CERo Therapeutics Aktie - CERO

CERo Therapeutics Holdings Inc (CERO) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,0747

( - )

Gebot

0,0747

Fragen

0,0748

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

0,0747

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome...

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF...

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH...

CERo Therapeutics Provides Shareholder Update

Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of...

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO...

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy...

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial...

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level;...

CERo Therapeutics Announces Trading on OTCQB Market

Company’s Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE...

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK:...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

CERO - Frequently Asked Questions (FAQ)

What is the current CERo Therapeutics Holdings Inc share price?

The current share price of CERo Therapeutics Holdings Inc is US$ 0,0747

What is the 1 year trading range for CERo Therapeutics Holdings Inc share price?

CERo Therapeutics Holdings Inc has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CERo Therapeutics Holdings Inc (CERO)

CERo Therapeutics Holdings Inc (CERO) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

CERO Neueste Nachrichten

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

CERo Therapeutics Announces Trading on OTCQB Market

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

CERo Therapeutics Announces Trading on OTCQB Market

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

CERo Therapeutics Announces Listing on OTC Markets

CERO - Frequently Asked Questions (FAQ)

CERO Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Warum ADVFN beitreten?

Alles, was seriöse Trader brauchen.

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS